About this episode

The episode explores the advancements in targeted therapy for extrapulmonary neuroendocrine carcinomas, highlighting its clinical potential and the importance of healthcare education.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/PBT865. EBAC/CME credit will be available until 7 January 2027. From Poor Prognosis to Emerging Clinical Potential: A Visual Journey of Targeted Therapy Innovation in Extrapulmonary Neuroendocrine Carcinomas In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. Disclosure information is available at the beginning of the video presentation.

People in this episode

Guest: Jaume Capdevila, MD, PhD

Topics covered

• targeted therapy
• extrapulmonary neuroendocrine carcinomas
• clinical potential
• healthcare education
• patient care

Keywords

• neuroendocrine carcinomas
• targeted therapy
• healthcare professionals
• continuing education
• patient care

Sponsors

Boehringer Ingelheim Pharmaceuticals, Inc.

Mentioned in this episode

Organizations: PeerView Institute for Medical Education, Accreditation Council for Continuing Medical Education, Accreditation Council for Pharmacy Education, American Nurses Credentialing Center

Explore listener stats, chart rankings, contacts and more on the PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast podcast page.